146 related articles for article (PubMed ID: 27571447)
1. Synthesis and Pharmacological Evaluation of [
Mu L; Müller Herde A; Rüefli PM; Sladojevich F; Milicevic Sephton S; Krämer SD; Thompson AJ; Schibli R; Ametamey SM; Lochner M
ACS Chem Neurosci; 2016 Nov; 7(11):1552-1564. PubMed ID: 27571447
[TBL] [Abstract][Full Text] [Related]
2. Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
Nakamura H; Yokoyama H; Takayanagi R; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):39-44. PubMed ID: 24470169
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron-5-HT
Price KL; Lillestol RK; Ulens C; Lummis SC
ACS Chem Neurosci; 2016 Dec; 7(12):1641-1646. PubMed ID: 27656911
[TBL] [Abstract][Full Text] [Related]
4. Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.
Lummis SC; Thompson AJ
Neuropharmacology; 2013 Oct; 73():241-6. PubMed ID: 23747573
[TBL] [Abstract][Full Text] [Related]
5. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
[TBL] [Abstract][Full Text] [Related]
6. Prolonged inhibition of 5-HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization.
Hothersall JD; Moffat C; Connolly CN
Br J Pharmacol; 2013 Jul; 169(6):1252-62. PubMed ID: 23581504
[TBL] [Abstract][Full Text] [Related]
7. Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
Del Cadia M; De Rienzo F; Weston DA; Thompson AJ; Menziani MC; Lummis SC
Bioorg Med Chem; 2013 Dec; 21(23):7523-8. PubMed ID: 24128813
[TBL] [Abstract][Full Text] [Related]
8. Mapping the Orthosteric Binding Site of the Human 5-HT
Jack T; Leuenberger M; Ruepp MD; Vernekar SKV; Thompson AJ; Braga-Lagache S; Heller M; Lochner M
ACS Chem Neurosci; 2019 Jan; 10(1):438-450. PubMed ID: 30149702
[TBL] [Abstract][Full Text] [Related]
9. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
Rojas C; Thomas AG; Alt J; Stathis M; Zhang J; Rubenstein EB; Sebastiani S; Cantoreggi S; Slusher BS
Eur J Pharmacol; 2010 Jan; 626(2-3):193-9. PubMed ID: 19836386
[TBL] [Abstract][Full Text] [Related]
10. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
[TBL] [Abstract][Full Text] [Related]
11. Toward biophysical probes for the 5-HT3 receptor: structure-activity relationship study of granisetron derivatives.
Vernekar SK; Hallaq HY; Clarkson G; Thompson AJ; Silvestri L; Lummis SC; Lochner M
J Med Chem; 2010 Mar; 53(5):2324-8. PubMed ID: 20146481
[TBL] [Abstract][Full Text] [Related]
12. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
Darmani NA; Zhong W; Chebolu S; Vaezi M; Alkam T
Eur J Pharmacol; 2014 Jan; 722():2-12. PubMed ID: 24513517
[TBL] [Abstract][Full Text] [Related]
13. Blockade of 5-HT3 receptors with granisetron does not affect trigeminothalamic nociceptive transmission in rats: Implication for migraine.
Sokolov AY; Sivachenko IB; Panteleev SS; Lyubashina OA
Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):34-41. PubMed ID: 28853174
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of (S)-[(18)F]fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptors.
Pithia NK; Liang C; Pan XZ; Pan ML; Mukherjee J
Bioorg Med Chem Lett; 2016 Apr; 26(8):1919-24. PubMed ID: 26979158
[TBL] [Abstract][Full Text] [Related]
15. Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron.
Steward LJ; Ge J; Bentley KR; Barber PC; Hope AG; Lambert JJ; Peters JA; Blackburn TP; Barnes NM
Br J Pharmacol; 1995 Sep; 116(2):1781-8. PubMed ID: 8528560
[TBL] [Abstract][Full Text] [Related]
16. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effect of granisetron on ventrolateral medulla neuron responses to colorectal distension in rats.
Panteleev SS; Martseva AА; Lyubashina OА
Eur J Pharmacol; 2015 Feb; 749():49-55. PubMed ID: 25595728
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus.
Maehara T; Matsumoto K; Horiguchi K; Kondo M; Iino S; Horie S; Murata T; Tsubone H; Shimada S; Ozaki H; Hori M
Br J Pharmacol; 2015 Feb; 172(4):1136-47. PubMed ID: 25377620
[TBL] [Abstract][Full Text] [Related]
19. The Binding of Palonosetron and Other Antiemetic Drugs to the Serotonin 5-HT3 Receptor.
Zarkadas E; Zhang H; Cai W; Effantin G; Perot J; Neyton J; Chipot C; Schoehn G; Dehez F; Nury H
Structure; 2020 Oct; 28(10):1131-1140.e4. PubMed ID: 32726573
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of Benzazepine-Based PET Radioligands (
Haider A; Herde AM; Krämer SD; Varisco J; Keller C; Frauenknecht K; Auberson YP; Temme L; Robaa D; Sippl W; Schibli R; Wünsch B; Mu L; Ametamey SM
J Nucl Med; 2019 Aug; 60(8):1167-1173. PubMed ID: 30683765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
